Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Urinary Bladder Neoplasms 5Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Melanoma 1Laryngeal Neoplasms 1Giant Cell Tumor of Bone 1Ganglioneuroblastoma 1Carcinoma 1Brain Neoplasms 1Alzheimer Disease 1

Interventions

pembrolizumab 54Nivolumab 50Ipilimumab 28Cyclophosphamide 16binimetinib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10fludarabine 9Radiosurgery 9relatlimab 8encorafenib 8Opdualag 8Biopsy 8aldesleukin 7Interleukin-2 7atezolizumab 6Immunotherapy 6Blood Specimen Collection 6cemiplimab 5CTLA-4 Antigen 5Bevacizumab 5trametinib 4fludarabine phosphate 4dabrafenib 4Temozolomide 4Paclitaxel 4Immune Checkpoint Inhibitors 4spartalizumab 3Surgical Procedures, Operative 3Metformin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Melanoma × Transurethral Resection of Bladder × Clear all
NCT07288112 2026-04-14

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Diakonos Oncology Corporation

Phase 1/2 Recruiting
35 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡